Abstract

Background: Chemotherapy drugs commonly used for cancer therapy, but chemotherapy has limitation due to side effects. Current studies suggest natural products are reducing the side effects of chemotherapy medicines. In this study, we examined the side effects of doxorubicin (Dox) in esophageal cancer cells (CSCs) derived tumors in vivo. Methods: Esophageal cancer cells (YMI) were treated in vitro with daphnetin (DAP) along with DOX. The MTT assay was used for estimating the cell viability and Annexin/7-AAD was used for the determination of apoptosis. Cell cycle arrest was conducted using the PI-staining method. The potential effect of DAP was evaluated by the estimation of oxidative stress such as total antioxidant capacity (TAC), malondialdehyde (MDA) and superoxide dismutase (SOD) and body weight in the xenograft mice. Results: DAP can protect Dox cell toxicity by suppressing cell apoptosis of ESCC. DAP arrest the cells as S-phase. In vivo experimental study showed that Dox simultaneously with DAP decreases the tumor size along with increased body weight in the nude mice compared to Dox alone treated group mice. Dox along with the DAP exhibited less systemic toxicity and reduced oxidative stress fraction circulation. Conclusion: The result suggests that daphnetin may be used as an adjuvant therapy to reduce the systemic toxicity of chemotherapeutic agents, such as DOX, in stem cell treatment with ESCC cancer.

中文翻译：

---

瑞香素对阿霉素治疗食管癌干细胞异种移植瘤小鼠的化学保护作用

 抽象的

背景：化疗药物常用于癌症治疗，但化疗因副作用而受到限制。目前的研究表明天然产物正在减少化疗药物的副作用。在这项研究中，我们在体内检测了阿霉素 (Dox) 对食管癌细胞 (CSC) 衍生肿瘤的副作用。方法：在体外用瑞香素 (DAP) 和 DOX 治疗食管癌细胞 (YMI)。 MTT测定用于估计细胞活力，Annexin/7-AAD用于测定细胞凋亡。使用PI染色方法进行细胞周期停滞。通过评估异种移植小鼠的氧化应激，如总抗氧化能力（TAC）、丙二醛（MDA）和超氧化物歧化酶（SOD）以及体重来评估DAP的潜在作用。结果：DAP可通过抑制ESCC细胞凋亡来保护Dox细胞毒性。 DAP 将细胞阻滞为 S 期。体内实验研究表明，与单独使用 Dox 治疗的小鼠相比，Dox 与 DAP 同时使用可减小裸鼠的肿瘤大小并增加体重。 Dox 与 DAP 一起表现出较低的全身毒性并减少了氧化应激分数循环。结论：结果表明，瑞香素可作为辅助疗法，以降低化疗药物（如 DOX）在 ESCC 癌症干细胞治疗中的全身毒性。